Journal of Experimental & Clinical Cancer Research · Published 2026-05-19 · DOI 10.1186/s13046-026-03740-4
Xianhui Meng, Fangmin Li, Hong Yu, Chunling Li, Yuxiao Sun, Hongying Wang, Guantong Liu, Jiashen Zhang, Lijun Hui, Fang Li, Shuping Wei, Yaopeng Wang, Zunling Li
Abstract Background CAR-T cell therapy faces substantial barriers in AML, yet the mechanisms by which AML evades CAR-T cell cytotoxicity—through tumor-intrinsic factors and microenvironmental suppression—remain poorly defined. IGSF9 has recently been identified as an immunosuppressive molecule selectively expressed on AML blasts, but its role in mediating resistance to CAR-T therapy is unknown. Methods We examined IGSF9 expression in AML cells upon CAR-T challenge and conducted in vitro and in vivo assays to define its functional impact on CAR-T cell activity. To overcome IGSF9-mediated suppression, we evaluated two therapeutic strategies: antibody-mediated IGSF9 blockade and the generation of IGSF9-specific CAR-T cells (IG9BBz). Results CAR-T–induced cytotoxic pressure upregulated IGSF9 on AML cells. IGSF9-positive AML cells exhibited resistance to CAR-T killing and impaired CAR-T persistence both in vitro and in vivo. Antibody blockade of IGSF9 restored CAR-T function in xenograft models. Moreover, IG9BBz CAR-T cells demonstrated potent and selective elimination of IGSF9-positive AML cells in both settings. Conclusions Our findings identify a cytokine-driven IGSF9 resistance circuit that suppresses CAR-T cell function in AML. Therapeutic disruption of this pathway through IGSF9 blockade or IGSF9-specific CAR-T cells restores antitumor immunity and provides complementary strategies to overcome CAR-T resistance in AML.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Meng, X., Li, F., Yu, H., et al. (2026). Targeting immunoglobulin superfamily member 9 (IGSF9) to overcome acute myeloid leukemia resistance to CAR-T therapy. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03740-4